According to media outlet Kurier Wilenski on November 15th, the Lithuanian government has decided to reject proposed amendments to the legislation regarding the prescription of e-cigarettes and their sale in pharmacies.
In response to this, former Minister of Health Aurelijus Veryga clarified, "There is a misconception about my suggestion regarding the sale of e-cigarettes in pharmacies, requiring a doctor's prescription. We are not proposing to move all e-cigarettes to pharmacies for prescription-only sales at this time. If e-cigarettes are recognized as medicinal products, they could be sold in pharmacies with a prescription, similar to the current practice with medical nicotine gum for smoking cessation. However, this is only a theoretical possibility, which is why I recommend a total ban on the sale of e-cigarettes in Lithuania."
Meanwhile, Gintaras Karanda, the head of the Department of Drug, Tobacco, and Alcohol Control, has noted that the legislation may restrict teenagers' use of e-cigarettes.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
